Every Form 4 that NovaBridge Biosciences American (NBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NBP filings page.
NovaBridge Biosciences (NBP) reported that Chief Business Development Officer Cao Sean Wuxiong sold 107,978 Ordinary Shares on September 9, 2026, at a reported converted price of $0.74 per Ordinary Share, leaving him with 266,467 Ordinary Shares held directly.
The footnotes state that the transaction involved 46,947 American Depositary Shares (ADSs) representing approximately 107,978 Ordinary Shares, sold in connection with the partial vesting of a restricted stock unit award on September 3, 2026, solely to satisfy tax withholding obligations. The reported sales price corresponds to an ADS price of $1.6908. No Rule 10b5-1 trading plan is reported.
NovaBridge Biosciences (NBP) reports that Chief Business Development Officer Cao Sean Wuxiong exercised previously granted restricted share units on September 3, 2026, converting 147,553 RSUs into 339,372 Ordinary Shares represented by American Depositary Shares. These RSUs come from grants of 408,933 units in 2025 and 181,280 units in 2026 that vest over four years. No trades are reported under a Rule 10b5-1 trading plan.
NovaBridge Biosciences (NBP) executive Xu Cong Claire, EVP Clinical Development, reported a set of related equity transactions. On August 30, 2026, 4,079 restricted share units were exercised into 9,382 Ordinary Shares, increasing direct holdings of Ordinary Shares to 28,558. On August 31, 2026, she then sold 3,282 Ordinary Shares in a sale in the open market or a private transaction at $0.79 per share, with the reported sales price corresponding to an ADS price of $1.8186.
NovaBridge Biosciences (NBP) director Lenz Robert A. reported an exercise of equity awards and a related share acquisition. On August 22, 2026, he exercised 7,486 restricted share units (RSUs), each convertible into one American Depositary Share (ADS), which together correspond to 17,218 Ordinary Shares. These exercises reduced his RSU balance but increased his direct non-derivative holdings to 17,218 Ordinary Shares, while he continues to hold 14,974 RSUs that remain outstanding and subject to vesting from an original grant of 22,460 RSUs awarded on August 22, 2025.
NovaBridge Biosciences reported that Chief Commercial Officer Mark Arnold Hagler received a grant of 949,050 2025 Employee Share Options, each representing a right to buy American Depositary Shares (ADS) at an exercise price of $1.93 per ADS. These options have an expiration date of July 8, 2036 and, according to the vesting terms, become exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026. The options relate to Ordinary Shares that may be represented by ADSs, where each 10 ADSs represent 23 Ordinary Shares. Following this award, Hagler holds 949,050 derivative securities of this type directly.
NovaBridge Biosciences reported that General Counsel Lin Liwei Lorraine received a grant of 254,780 2025 Employee Share Options, each representing a right to buy American Depositary Shares at an exercise price of 1.9300 per ADS. The options expire on 2036-07-08 and relate to an equivalent number of underlying Ordinary Shares represented by ADSs. The grant vests over five years, with 40% vesting on the second anniversary of February 1, 2026 and the balance in three equal annual installments thereafter.
NovaBridge Biosciences reported that Chief Executive Officer Srishti Gupta received a grant of 3,000,000 employee share options. These options give the right to buy Ordinary Shares at an exercise price of $2.01 per ADS-equivalent and expire on July 6, 2036. The award vests in four equal annual installments beginning on the first anniversary of July 1, 2026, and Gupta now holds 3,000,000 such options directly.
NovaBridge Biosciences senior executive Xu Cong Claire reported option exercises and a share sale. On July 4, 2026, she exercised derivative awards, converting 5,405 Restricted Share Units, represented by 5,405 American Depositary Shares (ADSs), into 12,432 Ordinary Shares at a conversion price of $0.00 per share.
On July 6, 2026, she completed an open-market sale of 4,485 Ordinary Shares at an average price of $0.89 per share, equivalent to an ADS sales price of $2.04. Following these transactions, she directly holds 298,101 Ordinary Shares, which the filing states are represented by 129,609 ADSs.
NovaBridge Biosciences director Fu Wei received equity-based compensation awards. On June 29, 2026, Fu Wei was granted 1,010,100 Restricted Share Units, each representing a contingent right to receive one American Depositary Share (ADS). These RSUs vest in equal annual installments on June 29, 2027 and June 29, 2028.
On the same date, Fu Wei was also granted three tranches of 2025 Employee Share Options covering 1,087,720, 1,087,720 and 725,140 underlying Ordinary Shares at an exercise price of $2.45 per share, expiring on June 29, 2036. Each option tranche vests, if at all, in eight equal quarterly installments after the issuer’s ADS 30-trading-day weighted average price reaches $8.00, $12.00 and $16.00, respectively.
NovaBridge Biosciences director and Chief Business Development Officer Cao Sean Wuxiong received new equity awards. He was granted 181,290 employee share options to buy Ordinary Shares (via American Depositary Shares) at an exercise price of $1.53 per ADS, expiring on June 22, 2036. These options vest in eight equal quarterly installments only after the 30-trading-day weighted average price of the company’s ADS is at or above $8.00.
He also received 181,280 restricted share units, each representing a contingent right to receive one ADS. These RSUs vest over four years, with one-fourth vesting on September 3, 2026 and the remainder vesting ratably over the following 12 quarters.
NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew reported a combination of option activity and share sales. He sold 8,494 Ordinary Shares in an open-market sale at $0.66 per share and, the prior day, exercised derivative awards into 10,302 Ordinary Shares represented by American Depositary Shares (ADSs). Following these transactions, he directly held 157,941 Ordinary Shares and 82,422 Restricted Share Units (RSUs), which each represent a right to receive one ADS.
NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported a mix of derivative exercises and a small open‑market sale of company stock. On June 1, 2026, she sold 3,494 Ordinary Shares at an average price of $3.94 per share in an open‑market transaction. On May 30, 2026, she exercised derivative awards to acquire additional Ordinary Shares, including Restricted Share Units (RSUs) covering 4,079 Ordinary Shares. After these transactions, she directly owns 290,154 Ordinary Shares and 32,637 RSUs. Footnotes state that Ordinary Shares are represented by American Depositary Shares (ADSs), where each 10 ADSs represent 23 Ordinary Shares, and her reported holdings correspond to 126,154 ADSs.
NovaBridge Biosciences director and officer Cao Sean Wuxiong reported an open-market sale of ADSs tied to equity compensation. He sold 9,304 American Depositary Shares (ADSs), representing approximately 21,399 ordinary shares, at a price expressed in ADS terms of $1.99. According to the footnotes, this sale was made in connection with the partial vesting of a restricted stock unit award on January 31, 2026, solely to cover tax withholding obligations related to that vesting. Following the transaction, he holds 35,073 ordinary shares, represented by 15,249 ADSs, indicating this was a routine tax-related disposition rather than a full exit.
NovaBridge Biosciences officer Mark Arnold Hagler reported an open-market purchase of 230,000 Ordinary Shares, represented by 100,000 American Depositary Shares (ADSs). The weighted average purchase price was $2.51 per ADS, with individual trades between $2.44 and $2.54. Following the transaction, he directly holds 230,000 Ordinary Shares.